R&D Leadership Summit to Accelerate R&D Productivity Enhancement Opportunities

R&D Leadership Summit

The R&D Leadership Summit convenes industry experts and leaders from the biopharmaceutical field to delve into pivotal topics shaping the trajectory of research and development. On March 4th, our CEO, Colin Hill, will be part of a panel to discuss the transformative potential of AI and its profound implications in drug discovery. The discussion will center […]

Join Aitia at the GAP-Net Site Optimization Conference in New Orleans

GAP NET SITE OPTIMIZATION

Join Aitia at the GAP-Net Site Optimization Conference in New Orleans, Louisiana on Feb 28 – March 1, 2024. This conference is exclusively focused on enhancing clinical trials, bringing together clinical research leaders and executive teams from prominent Alzheimer’s and Parkinson’s disease clinical trial sites across North America, along with pharmaceutical sponsors, CROs, and other […]

Unveiling the AI Dominance in Biopharma: STAT Post JPM Conference Insights

At health care’s biggest investor conference, AI’s high hopes collided with skepticism - STAT article

JPM conference has echoed discussions about AI across the biopharmaceutical landscape. Catch up on key insights shared in the latest STAT article titled: “At Health Care’s Biggest Investor Conference, AI’s High Hopes Collided with Skepticism.” Sanofi’s chief executive, Paul Hudson, revealed the widespread integration of AI within the company: “More than 11,000 people across the […]

Cytoskeleton Genes Underlying Onset and Progression in Multiple Neurodegenerative Disorders Discovered through Aitia’s Digital Twins to be Presented at SfN 2023

Somerville, MA, November 8, 2023: Aitia, the leader in the application of Causal AI and Digital Twins to discover and develop new drugs, announced today that data from its neurodegenerative disorders Digital Twins, including Alzheimer’s Disease (AD) and Parkinson Disease (PD), will be presented at the upcoming Society of Neuroscience (SfN) Conference, being held from […]

Prediction of Amyloid PET Positivity from Blood-Based Biomarkers, Proteomics, and Clinical Data Discovered through Aitia’s Digital Twins to be Presented at CTAD 2023

Somerville, MA, October 19, 2023: Aitia, the leader in the application of Causal AI and Digital Twins to discover and develop new drugs, announced today that data from its Alzheimer’s Disease Digital Twins will be presented at the upcoming Clinical Trials on Alzheimer’s Disease (CTAD), being held from October 24-27, 2023 in Boston. Aitia’s Digital […]

Prediction of Amyloid PET Positivity from Blood-Based Biomarkers, Proteomics, and Clinical Data Discovered through Aitia’s Digital Twins to be Presented at CTAD 2023

CTAD 2023 1

We are delighted to announce that Aitia will be at the Clinical Trials on Alzheimer’s Disease conference (CTAD) being held from October 24-27 in Boston, MA. We will be presenting a poster focused on prediction of Amyloid PET positivity of Alzheimer’s Disease (AD) through Gemini Digital Twins of AD patients, based on blood-based biomarkers and […]

Colin Hill Keynote at Servier Paris-Saclay R&D Institute in France

Servier Aitia

On July 20th, we had the privilege to visit the cutting-edge Servier Paris-Saclay R&D Institute in France, where our CEO, Colin Hill delivered a keynote titled: “Why AI and Digital Twins will Drive the Discovery and Development of the Next Generation of Breakthrough Drugs“. The open conference was a remarkable display of Servier’s dedication to foster a collaborative […]